SEARCH · Search PubMed

Results for “Dexfenfluramine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources

PubMed1990

[Drug therapy of obesity--results of treatment with dexfenfluramine].

The paper presents the results of treatment in 22 obese persons with hypoenergetical nutrition of 4200 kJ with the simultaneous application of dexfenfluoramine in the daily dose of 30 mg in the course of three months. During this period of time an average weight loss of 7.5 kg was achieved, and a loss of 10 kg and more in one third of the patients. The controlled laboratory parameters did not show any significant deviations, and side effects in the form of mouth dryness and diarrhea were rare, and of a lighter intensity so that they did not demand the stop of therapy. When correctly indicated, dexfenfluoramine presents a valuable supplement in the therapeutic arsenal for obesity treatment, because thanks to its anorexigenic effect it eases the conducting of hypoenergetical nutrition and improves the treatment effect of this pathological condition.

Adult↗

PubMed1989

Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine.

Explore the source record for details and available documents.

Adult↗

PubMed1988

Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.

We have evaluated the effects of dextrofenfluramine treatment on body weight control during a 90 day period, in obese patients on a calorie-restricted diet. The weight loss in dextrofenfluramine-treated patients was significantly higher than in placebo group. The rate of weight loss was linear up to the end of the trial in d-fenfluramine patients. Neural disturbances (vertigo, headache, depression) were the most frequent side effects observed in both the d-fenfluramine and in the placebo-treated groups, without significant differences between the groups. A total number of 23 patients in the dextrofenfluramine group and 20 patients in the placebo group complained side effects. Six patients (five in the d-fenfluramine group and one in the placebo group) discontinued the treatment, due to the side effects. No modifications of the biochemical parameters considered (fasting blood glucose, bilirubin, alkaline phosphatase, creatinine, blood cell counts, asparate-amino transferase (AST), alanine-amino transferase (ALT), total plasma and HDL cholesterol, and triglycerides) were observed at the end of the trial. A significant reduction of total serum cholesterol was observed in both groups at the end of the period of treatment. In conclusion, dextrafenfluramine was proved to be in short term trials an effective and safe tool in overweight control in obese patients.

Adult↗

PubMed1988